Biomarker Type: Proteomic
-
A phase 2 adjuvant trial of gi-4000 plus gem vs. Gem alone in ras mutation+ resected pancreas cancer: r1 subgroup and proteomic analysis
-
VeriStrat has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
-
A plasma proteomic signature predicts outcomes in a Phase 3 study of gemcitabine (G) + cisplatin (C) ± sorafenib in first line stage IIIB or IV non-small cell lung cancer (NSCLC)
-
EarlyCDT—Lung Test: Improved Clinical Utility Through Additional Autoantibody Assays
-
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
-
Evaluation of VeriStrat Signature in Advanced Bronchioloalveolar Carcinoma (BAC): A Pooled Analysis of IFCT-0401 and 0504 Trials
-
Pre-treatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affect sensitivity of lung cancer cell lines to EGFR-TKIs
-
Clinical Validation of an Autoantibody Test for Lung Cancer
-
The proteomic classifier VeriStrat identifies advanced non-small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib
-
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab